Engflag

Claricine

Quick links to important sections

Claricine

Claricine_DE

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Claricine

Property Description
Active ingredient Clarithromycin
Form Oral tablets (immediate/extended-release), Oral suspension, Powder for injection
Pharmacological class Macrolide antibiotic
Common use Treatment of bacterial infections
Origin Semisynthetic

What Type of Medicine is Claricine (Clarithromycin)?

Claricine is a prescription-only medication identified by its active ingredient, Clarithromycin, which is classified as a macrolide antibiotic. This compound is recognized for its stability and enhanced absorption compared to older macrolides. Clarithromycin belongs to the semisynthetic macrolide class of antimicrobials, meaning it was developed through chemical modification of the naturally occurring macrolide compound Erythromycin. The primary, overarching purpose of the drug is to counteract bacterial infections caused by microorganisms susceptible to the macrolide class. Macrolides represent a crucial treatment pathway, especially for patients who are allergic to the penicillin-class of antibiotics.

Composition and Available Forms of Clarithromycin

The foundation of Claricine is its single-ingredient composition, containing only the molecular entity Clarithromycin as the active therapeutic agent. Clarithromycin is considered an essential medicine for managing health needs. To facilitate effective delivery across different age groups and treatment needs, Claricine is produced in several dosage forms for systemic use, primarily including oral tablets and a liquid oral suspension. The tablets are specifically manufactured in both immediate-release and extended-release variations, which differ in how quickly the active ingredient is delivered and absorbed.

How Does Claricine Generally Help the Body?

Claricine’s general benefit is derived from its ability to stop the growth and reproduction of bacteria responsible for causing an infection. It achieves this by exerting a bacteriostatic effect, which means it halts the proliferation of the target microorganisms rather than rapidly killing them outright. By preventing the growth and multiplication of the invading bacteria, the drug reduces the overall infectious burden, effectively enabling the body’s own immune system to successfully clear and resolve the underlying illness. This interruption of bacterial processes is essential for achieving a successful therapeutic outcome in the management of susceptible infections, such as those impacting the respiratory tract.

What side effects are possible with Claricine?

Possible Side Effects and Safety Information for Claricine

Claricine's official safety profile highlights a range of potential side effects, primarily affecting the gastrointestinal and nervous systems. Most frequently documented adverse reactions (Common, ge1% to <10%) include diarrhea, nausea, vomiting, abdominal pain, and headache. A very common ( ge10%) adverse event is dysgeusia (altered or metallic taste).

Serious and Clinically Significant Adverse Reactions

Regulatory documents emphasize the risk of rare but serious adverse events, including:

  • Cardiac Events: Claricine has been associated with QT interval prolongation and potentially fatal cardiac arrhythmias, such as Torsades de Pointes.
  • Hepatotoxicity: Liver dysfunction, ranging from cholestatic jaundice to, in rare instances, fatal hepatic failure, has been reported.
  • Severe Skin Reactions: Serious cutaneous adverse reactions, including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and DRESS (Drug Rash with Eosinophilia and Systemic Symptoms), have occurred.
  • Gastrointestinal Complications: Severe and prolonged diarrhea can be a symptom of Clostridioides difficile-associated diarrhea (CDAD), which may range from mild to life-threatening.

Safety Restrictions and Considerations

Claricine is contraindicated in patients with a history of QT prolongation, ventricular cardiac arrhythmia, uncorrected low potassium or magnesium levels, or previous Claricine-associated cholestatic jaundice/hepatic dysfunction. It is also prohibited for use with several co-administered drugs due to the risk of serious, sometimes fatal, drug interactions (e.g., specific HMG-CoA reductase inhibitors, colchicine, and cisapride).

Population-Specific Notes: Caution is advised in patients with renal or hepatic impairment, and in geriatric patients who may be more susceptible to drug-associated cardiac effects. A regulatory safety signal has indicated an increased risk of long-term cardiovascular mortality following a course of the drug in certain patients with pre-existing heart disease.

Overdose and Emergency Response

A Claricine (Clarithromycin) overdosage is documented in regulatory labeling as primarily resulting in gastrointestinal symptoms. These common manifestations of overdose may include abdominal pain, nausea, vomiting, and diarrhea.

The official regulatory guidance emphasizes that immediate medical attention is required for any suspected overdose. Emergency medical services must be contacted immediately if a person exhibits life-threatening symptoms, which are described in official documentation as including collapse, having a seizure, experiencing trouble breathing, or being unable to be awakened. Separately, the poison control helpline must be contacted for specific guidance in all instances of overdose.

Management of overdose is based on regulatory directives for supportive measures and the prompt elimination of unabsorbed drug. The official prescribing information states that there is no specific antidote available for Clarithromycin overdosage. Furthermore, regulatory context notes that drug concentrations are not expected to be appreciably affected by the use of hemodialysis or peritoneal dialysis. The overdose section does not detail distinct population-specific risks for pediatric, elderly, or renally impaired patients.

Therapeutic Uses of Claricine

What Claricine Treats: Main Uses and Benefits

Claricine (clarithromycin) is a macrolide antibiotic indicated for the management of various bacterial infections. This medication is primarily used to address infections in numerous parts of the body, including the skin, ears, sinuses, lungs (such as pneumonia and bronchitis), and throat. The goal of treatment is to help manage the infection and its associated symptoms.

A key clinical scenario involves its use in combination with other agents for the management of Helicobacter pylori (H. pylori) infection, which is linked to stomach ulcers. It is also used in regimens for the prophylaxis and treatment of Mycobacterium avium complex (MAC) infection. As an antibiotic, Claricine does not address viral conditions like the common cold or flu.

Quick Fact: Bacterial Respiratory Symptoms The antibiotic is a therapeutic option used to help manage respiratory infections, such as those causing symptoms of bronchitis or pneumonia.

Eligibility and Restrictions for Use

The eligibility for Claricine (clarithromycin) is strictly defined by official regulatory labeling, outlining specific populations who must not use the medicine and those who require conditional use.

Claricine is contraindicated in patients with a known allergy to clarithromycin or any macrolide antibiotic, or a history of drug-induced cholestatic jaundice. Absolute non-eligibility also applies to individuals with a known history of QT prolongation, certain ventricular arrhythmias, or uncorrected low potassium or magnesium levels. It is also prohibited for use in patients with severe hepatic failure combined with renal impairment.

Use is not recommended in pregnant women unless the anticipated clinical benefit clearly outweighs the potential hazard to the fetus. Safety has not been established for infants exposed during breastfeeding.

Age-related limitations apply: use is not established in children younger than six months. For children under 12 years, the tablet formulation is generally not suitable. Caution is required when prescribing to older adults, who may be more susceptible to cardiac and renal effects. Patients with moderate to severe renal or hepatic impairment must use the medicine with caution, and a dosage adjustment is typically required for severe renal dysfunction.

What should I know about interactions with other medicines?

Clarithromycin is a strong inhibitor of the Cytochrome P450 3A (CYP3A4) enzyme and the P-glycoprotein transporter. This activity significantly affects the metabolism of numerous co-administered medicines, leading to potential elevations in their systemic concentration and increasing the risk of serious adverse events. Due to this mechanism, certain combinations are officially designated as contraindicated.

Contraindicated Medicinal Products (Do Not Combine) Clinically Significant Interaction Risk
HMG-CoA Reductase Inhibitors (Statins): Lovastatin, Simvastatin Oral Anticoagulants (e.g., Warfarin): Requires frequent INR monitoring and dose adjustment due to potentiation of effects.
Ergot Alkaloids: Ergotamine, Dihydroergotamine Colchicine: Use is contraindicated in patients with renal or hepatic impairment.
QT-Prolonging Drugs: Pimozide, Cisapride, Astemizole, Terfenadine, Domperidone Digoxin, Midazolam (oral), Antiarrhythmics: Requires dose adjustment and/or close clinical and laboratory monitoring.

Co-administration with CYP3A4 inducers such as rifampin, phenytoin, and carbamazepine may decrease Clarithromycin levels. Additionally, when co-administered with Zidovudine, the drugs must be separated by at least 2 hours. Consultation with a healthcare professional is necessary before initiating treatment with any interacting product.

Mechanism of Action

How Claricine Works: Mechanism of Action

Clarithromycin functions as a reversible inhibitor by directly targeting the 23 S ribosomal RNA within the bacterial 50 S ribosomal subunit. This molecular interaction physically blocks the ribosome's tunnel, thereby inhibiting the enzyme peptidyltransferase and arresting the elongation of peptide chains. This cascade immediately halts the bacteria's ability to synthesize proteins required for growth, resulting in a bacteriostatic effect.

The overall effect involves the action of the parent compound and its microbiologically active metabolite, 14-hydroxy-clarithromycin, both contributing to ribosomal inhibition. The compound actively concentrates in host immune cells, such as phagocytes, facilitating its delivery to the anatomical site of microbial activity. This mechanism helps ensure a consistent local inhibitory effect.

The drug's action is constrained when bacteria acquire genetic changes that modify the rRNA binding site or activate efflux pumps. These transport mechanisms actively remove the drug from the cell before it can reach the ribosomal target, functionally overriding the core inhibitory mechanism and resulting in unhindered bacterial proliferation.

Dosage and Administration Information

How Claricine Is Used: Official Administration Guidelines

Claricine (Clarithromycin) administration follows specific protocols addressing the drug's various forms, routes, and required intake conditions. It is available for oral intake (immediate-release tablets, extended-release tablets, and suspension) and for intravenous (IV) infusion, reserved for patients who require parenteral therapy.

Standard Dosing and Frequency

Instruction Detail
Standard Adult Oral Dose (IR) 250 mg to 500 mg per dose.
Standard Adult Oral Dose (ER) 1000 mg once daily.
Frequency Pattern Immediate-Release forms and IV are typically dosed every 12 hours (twice daily); Extended-Release forms are dosed every 24 hours (once daily).
Pediatric Dosing Based on weight, commonly 7.5 mg/kg twice daily, not exceeding the maximum adult dose of 500 mg per dose.

Administration Conditions and Adjustments

Contextual Intake Rules

The relationship to food varies by form. Immediate-release tablets and suspension may be taken with or without food as the extent of absorption is not significantly affected. However, the Extended-Release tablet formulation must be taken with food to ensure the active ingredient is released and absorbed correctly.

Procedural Adjustments

Patients with severe renal impairment (creatinine clearance below 30 mL/min) require a mandated dose reduction by half of the standard total daily dosage. Furthermore, Extended-Release tablets must be swallowed whole and must not be crushed, chewed, or broken, which would compromise the controlled-release mechanism. Treatment courses typically range from 6 to 14 days for common infections, though management of Mycobacterium avium complex (MAC) may require indefinite, long-term use.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Claricine

Evidence for Use in Respiratory Tract Infections

Research on Claricine's role in treating community-acquired pneumonia, acute bronchitis, and sinusitis is based on controlled trials. These studies primarily compared Claricine to other standard antibiotics and monitored short-term outcomes like symptom changes and bacteriologic eradication (bacterial clearance). Data show patterns related to how symptom patterns evolved in the observed populations. Researchers track physical discomfort outcomes, such as fever or cough, over the short-term follow-up periods (typically up to 35 days).

The application of these research findings is constrained by the rising rates of macrolide resistance in common bacterial organisms. Furthermore, long-term effects are not fully established regarding recurrence rates or the durability of the response beyond the immediate post-treatment window.

Evidence for Use in H. pylori and Ulcer Management

Claricine was studied for its application as one part of a multi-drug regimen to help eliminate Helicobacter pylori bacteria. The key research focus is on the measured rate of bacteriological clearance, confirmed several weeks after treatment completion. Successful clearance of the bacteria was reported to be related to the susceptibility of the H. pylori strain to Claricine.

This evidence is limited because Claricine is only studied as a component within combination therapy, not as a standalone treatment. The findings reported in the research may be highly affected by the high and increasing rates of clarithromycin resistance found globally, which can reduce measured clearance rates.

Evidence for Use in Mycobacterium avium complex (MAC) Infection

Research examined Claricine's use in treating and preventing MAC infection, particularly in patients with advanced immune conditions (e.g., advanced HIV infection). Studies monitored bacteriological response as a key outcome when Claricine was part of a long-term, multi-drug therapeutic strategy. They also monitored the potential for the emergence of drug resistance during the course of the extended therapy.

The results apply primarily to the populations studied; research in this area is concentrated in individuals who are immunocompromised. Because the treatment duration is long-term (often a year or more), and Claricine is always used with other agents, long-term effects are not fully established for its individual contribution to overall outcomes.

Frequently Asked Questions (FAQ)

Common questions about Claricine (FAQ)

Q: What is Claricine used for?

A: Claricine is indicated for the treatment of certain bacterial infections. It works by targeting specific types of bacteria. The exact conditions treated are specified in the official product labeling.

Q: How should I store Claricine?

A: Claricine should generally be stored at room temperature, away from moisture and heat. It is important to review the specific storage instructions provided on the bottle or in the package insert for your medication.

Q: Can I drink alcohol while taking Claricine?

A: The combination of alcohol and Claricine may increase the risk of side effects, such as dizziness or stomach upset, in some individuals. It is best to discuss your alcohol consumption with a healthcare provider while using this medication.

Q: What if I miss a dose of Claricine?

A: If a dose is missed, it should be taken as soon as it is remembered. However, if it is close to the time for the next scheduled dose, the missed dose may be skipped, and the regular dosing schedule should be resumed. Do not attempt to take two doses at once. Specific instructions for a missed dose are outlined in the patient information leaflet.

How should Claricine be stored and disposed of?

Storage Requirements

Official regulatory guidelines define specific conditions for storing clarithromycin to maintain its stability and effectiveness. Tablets must be kept at a controlled room temperature, typically 20 C to 25 C (68 F to 77 F), and must be protected from light, moisture, and excess heat. The medication should remain in its original, tightly closed container.

Stability and Handling

For the oral suspension, the powder or granules must be stored below 25 C before mixing. Once prepared, the liquid suspension is stable for 14 days and must not be refrigerated or frozen. All forms of the medicine must be stored out of the sight and reach of children.

Disposal Instructions

Unused, expired, or unneeded clarithromycin must be safely disposed of according to the guidelines set by national regulatory agencies (such as the FDA guidelines). The official procedure generally involves throwing the medicine away, often after returning it to a pharmacist or collection point, rather than flushing it down a toilet or pouring it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Claricine found in:

A-Z Index: